Cethromycin Against Liver-Stage Malaria (CALM)

Eliminating Malaria Relapse Without Testing Barriers

Cethromycin HCl is a short-course, Glucose-6-Phosphate-Dehydrogenase (G6PD) deficiency testing-independent oral therapy designed to eliminate dormant liver-stage malaria and prevent relapse—without the safety and deployment constraints of current radical-cure options.

LEARN MORE >

AliquantumRx: Transforming Liver-stage Malaria Treatment

A Near-Clinical Entry Company Built for Efficient Human Proof-of-Concept

AliquantumRx is supported with over $6M in non-dilutive funding for IND-enabling studies and early clinical development, benefitting from extensive prior human safety exposure (over 5,000 subjects) to cethromycin free base, and is executing a clear regulatory path toward human proof-of-concept and potential Priority Review Voucher eligibility.

LEARN MORE >

Photos are from PHIL/CDC

© AliquantumRX Inc. 2022. All Rights Reserved.